Dexcom (DXCM) | Stock Overview & Key Data
Dexcom Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $164.86 on November 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dexcom
DXCM
|
23.76B Large-cap | -3.13% | 20.43% | 11.88% | 12.92% | 11.54% | -8.07% | -42.07% | -27.92% | 315.26% | 2,149.85% | 2,129.88% |
| 160.70B Large-cap | -2.02% | 4.97% | -19.35% | -30.98% | -28.60% | -34.98% | -16.97% | -20.08% | 135.84% | 255.56% | 329.52% | |
|
Stryker
SYK
|
126.25B Large-cap | 2.13% | 0.38% | -11.91% | -13.33% | -11.56% | -17.25% | 6.06% | 22.47% | 172.95% | 440.98% | 592.85% |
|
Medtronic plc
MDT
|
107.58B Large-cap | -0.38% | 5.55% | -8.91% | -18.45% | -16.31% | -8.10% | -10.04% | -34.92% | -4.68% | 110.00% | 59.60% |
| 97.63B Large-cap | -3.98% | -11.24% | -33.00% | -49.28% | -50.63% | -52.97% | -13.64% | 9.04% | 108.58% | 590.87% | 133.50% | |
| 48.52B Large-cap | 0.50% | 6.02% | 3.26% | 3.48% | 1.11% | 13.25% | -7.43% | -15.49% | 159.09% | 507.93% | 2,151.59% |
Ownership & Short Interest
Calculate Your Dexcom Investment Returns
Long-Term Investment Performance Analysis
Dexcom stock price in Jul 2016 was $21.97, A $1,000.00 lump sum investment in Dexcom made 9 years ago would be worth approximately $3,378.24 today, representing a outstanding return of 237.82%. This translates to an annualized return (CAGR) of 13.07%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is DXCM's 52-week high and low?
- In the last 52 weeks, Dexcom reached a high of $89.98 (on July 30, 2025) and a low of $54.11 (on November 7, 2025).
- What is the market cap and P/E ratio for DXCM?
- Curious about Dexcom's size and valuation? Its market capitalization stands at 23.76B. When it comes to valuation, the P/E ratio (trailing twelve months) is 30.03, and the forward P/E (looking ahead) is 20.59.
- Does DXCM pay dividends? If so, what's the yield?
- As for dividends, Dexcom isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dexcom's main competitors or similar companies to consider before investing?
When looking at Dexcom, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT160.70B Healthcare Medical Devices -34.98% -16.97% Stryker
SYK126.25B Healthcare Medical Devices -17.25% 6.06% Medtronic plc
MDT107.58B Healthcare Medical Devices -8.10% -10.04% Boston Scientific
BSX97.63B Healthcare Medical Devices -52.97% -13.64% Edwards Lifesciences
EW48.52B Healthcare Medical Devices 13.25% -7.43% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dexcom Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Dexcom's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 34.50%, the Debt to Equity ratio from the most recent quarter is 50.85, and its Gross Profit Margin stands at 62.93%.
- What is the recent revenue and earnings growth for DXCM?
- Looking at Dexcom's growth, its revenue over the trailing twelve months (TTM) was $5B. Compared to the same quarter last year (YoY), quarterly revenue grew by 13.10%, and quarterly earnings saw a YoY growth of 76.20%.
- How much of DXCM stock is held by insiders and institutions?
- Wondering who owns Dexcom stock? Company insiders (like executives and directors) hold about 0.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 101.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.